ELI Lilly Biotechnology appears in San Diego, California, the United States on March 1, 2023.
Mike Blake Reuters
Eli Lily On Tuesday he said Daily pregnancy pills for weight loss Patients with obesity and type 2 diabetes helped in weight in a late stage experience, meet the main goal of studying and wiping the road to the company A file to agree to the medicine Globally.
Treatment is close to becoming a new alternative to the needle-free in the highly profitable market for weight loss and diabetes called GLP-1S. The most convenient pill can enhance the supply of treatments and are easy to access from the price of the weekly weekly injection that is currently dominating the space. Also, Eli Lilly will not come with nutritional restrictions, unlike orally similar oral treatment from the large Noufo Nordsk competitors.
The highest dose of birth control pills, or patients, patients, helped lose 10.5 % of their weight, or 22.9 pounds, on average in 72 weeks, compared to weight loss by 2.2 % among those who took a fake medicine. The loss of the drug weight in the study was 9.6 % when analyzing all patients regardless of stopping.
Eli Lili has achieved other experience goals of helping patients reduce the hemoglobin A1C, a measure of blood sugar levels. By the end of the study, most patients no longer meet the standards of type 2 diabetes based on this scale. It appears that the average side effects and the interruption of the treatment in the study, called ATAIN-2, are generally in line with two recent experiments in the third stage of Eli Lily.
Elie Lily now has now had a full clinical trial data package required to submit it to obtain approvals for the drug to manage chronic weight with global organizers. The drug giant expects the birth control pills around the world “this time next year”, CEO David Rex Tell CNBC in early August.
In an interview, the chief scientific employee at Eli Lily Daniel Scofaronski said that the pill was “” unprecedented effectiveness “in patients with obesity and type 2 diabetes, who usually face more difficulty in losing compared to those who do not have diabetes. Advance it.
“The current GLP-1 injection showed a greater weight loss from the Eli Lilly pills, but the presence of oral option provides more than 10 % For patients who suffer from both obesity and type 2 diabetes “” actually very good, and this is positive, “this is positive.”
But she described it as “related” that more patients – 10.6 % of those with the highest dose – stop taking birth control pills due to side effects compared to what was seen in separate studies on current injection, Eli Lily Zepbound and Novo NordskAnd wegovy. Abuovian said that the patients and their descriptions will have to assess the risks and benefits of birth control pills and injections when identifying any, including comfort and side effects.
The side effects of Eli Lili grains were intestinal basis, such as nausea and vomiting, and were light to moderate in severity. About 23.1 % of those who took the highest dose of vomiting, while 36.4 % and 27.4 % have nausea and diarrhea, respectively.
About 20 % of patients have stopped taking birth control pills for any reason, which is almost the same as the places of a placebo. Skovronsky said this reflects a set of reasons regardless of side effects. These can include patients who want to stop participating in an experiment because they were able to reach another obesity drug, or those who have not lost enough weight because they are taking a lower dose of the drug.
But he said that most patients remain on the medicine, and he said, “The most important thing here is the size of this opportunity,” referring to the number of people around the world can benefit from OrporiPron. More than 100 million adults in the United States alone suffer from obesity, according to the Centers for Disease Control and Prevention Data.
Apovian said it is very enthusiastic about an oral option that enters the market not because of the amount of weight loss it can enhance, but rather the possibility of expanding the scope of access to obesity treatments, especially since the birth control pills are much easier than manufacturing than injections. Apovian hopes that the ELI Lilly pill will be priced from the injection – which cost about $ 1,000 per month before insurance – and receives wider insurance coverage.
Tuesday’s results are The third group of late stage data The company issued one this year. In April, the pill succeeded in a The third stage is shorter Diabetics without obesity.
Earlier this month, the drug also achieved separate study goals on obese and not diabetes, but it was not less than Wall Street’s expectations. Dr. Jaimi Al -Manduz, medical director of the Weight Wellness program at the UT Southweestern Medical Center, said that the loss of birth control pills was higher in that experience compared to Tuesday’s data, but “this is expected”, given the differences in the patient’s groups.
In general, some doctors have described the loss of birth control pills in experiments, and some analysts say it will remain an applicable competitor in space due to factors such as the easiest manufacturing and lack of nutritional restrictions.
“It is possible that the rest and the lack of fasting requirements and water restrictions with or Ovuor Glipron are one of the main pesticides when people think about other oral factors as effective similar to weight change and A1C levels,” said Mandos.
He said that the birth control pills create additional opportunities to care for individual patients “where there is more autonomy.” For example, some people may be reluctant to do weight loss.
Detailed experimental data
The experiment followed more than 1,600 people, who were randomly chosen to receive three different targeted doses of ELI Lilly or fake. Patients began a dose less than the drug and gradually increased at four weeks to reach the final target dose.
More than 50 % of patients with the highest dose of Eli Lily’s treatment has at least 10 % of their weight in the experiment, while 28.4 % of these participants lost at least 15 %. Through different groups, the company did not reveal the number of patients who lost at least 5 % of their weight.
Howard Winterop, the Clinical Director of the Center for Cardiovascular Diseases at New York University, said that Ovor Glipron “may not be the answer” for patients with great weight gain. But he said: “For many people who need to lose a good amount of weight, the loss of 10 % can make a big difference.”
Orforglipron A1C reduced an average of 1.3 % to 1.8 % in different doses in 72 weeks, from the start of 8.1 %. About 75 % of the participants who obtained the highest A1C dose achieved 6.5 % or less, which is in or less than what the American Diabetes Association defines as diabetes.
Eli Lilly also improves cardiovascular risk.
“We now have a study after studying with the GLP-1 stimuli that turned out to reduce the very important results, which I do every day as a preventive cardiologist,” said Wittop. “I do my best to prevent them from developing a heart attack, stroke and death.”
Elie Lili works in a similar way with Wegovy, OzemPIC and Novo Nordisk, targeting the intestinal hormone called GLP-1 to suppress a person’s appetite and regulate blood sugar. Novo Nordisk also seeks the approval of an oral version of Wegovy, which can come by the end of the year.
But unlike these three drugs, ELI Lilly is not a pharmacy for peptide. This means that it is absorbed more easily by the body and does not require nutritional restrictions such as Rybelsus or Wegovy orally.
https://image.cnbcfm.com/api/v1/image/108184894-17550206822025-08-12t173750z_397057516_rc26lz9i31dr_rtrmadp_0_usa-texas-eli-lilly.jpeg?v=1755020703&w=1920&h=1080
Source link